Sökning: "Anaplastic lymphoma kinase"
Visar resultat 1 - 5 av 18 avhandlingar innehållade orden Anaplastic lymphoma kinase.
1. Anaplastic Lymphoma Kinase mutations and downstream signalling
Sammanfattning : The oncogene Anaplastic Lymphoma Kinase (ALK) is a Receptor Tyrosine Kinase (RTK) and was initially discovered as the fusion protein NPM (nucleophosmin)-ALK in a subset of Anaplastic Large Cell Lymphomas (ALCL). Since then more fusion proteins have been identified in a variety of cancers. LÄS MER
2. Exploiting Drosophila as a model system for studying anaplastic lymphoma kinase in vivo
Sammanfattning : Anaplastic Lymphoma Kinase (ALK) is a Receptor Tyrosine Kinase (RTK) and an oncogene associated with several human diseases, but its normal function in humans and other vertebrates is unclear. Drosophila melanogaster has an ALK homolog, demonstrating that the RTK has been conserved throughout evolution. LÄS MER
3. Investigating the function of Anaplastic Lymphoma Kinase
Sammanfattning : Anaplastic Lymphoma Kinase (ALK) was discovered in 1994, as a chromosomal translocation, t(2;5)(p23;q35), often seen in Anaplastic Large Cell Lymphomas (ALCL). Since then ALK has been extensively studied in this disease as well as in different model organisms. LÄS MER
4. Mechanistic Implications and Characterization of Anaplastic Lymphoma Kinase (ALK) mutations in Neuroblastoma
Sammanfattning : Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that was first reported as a fusion partner of nucleophosmin in Anaplastic large cell lymphoma in 1994. ALK is involved in myriad of cancers including neuroblastoma which is the most common extracranial solid tumor affecting young children. LÄS MER
5. Epidemiological and clinical aspects of T-cell lymphoma
Sammanfattning : T-cell lymphoma (TCL) is a rare group of malignancies and one of the important aims in this thesis has been to broaden the general knowledge of TCL with descriptive patient data. Main focus has been to examine prognosticfactors for overall survival (OS) and progression-free survival (PFS), and to evaluate different treatment approaches and follow-up (FU) after treatment. LÄS MER